Abstract
Aims: To this end, we are conducting a randomised controlled trial that examines the effects of a weight-based dosing of a full-spectrum CBD oil on social communication, behavioural, and neurophysiological outcomes in autistic children.
Methods: A total of 34 autistic children (determined by a priori power analysis), aged 5 to 12 years, are enrolled in this 12-week randomised, double-blind, placebo-controlled, cross-over, Phase I/II clinical trial. Participants are diagnosed with autism spectrum disorder in accordance with the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V). Participants are randomised to receive either weight-based dosing of 10 mg/kg/day of Medigrowth CBD100, or placebo, for the first phase, followed by an 8-week washout before commencing the second 12-week treatment phase (cross-over).
Methods: A total of 34 autistic children (determined by a priori power analysis), aged 5 to 12 years, are enrolled in this 12-week randomised, double-blind, placebo-controlled, cross-over, Phase I/II clinical trial. Participants are diagnosed with autism spectrum disorder in accordance with the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V). Participants are randomised to receive either weight-based dosing of 10 mg/kg/day of Medigrowth CBD100, or placebo, for the first phase, followed by an 8-week washout before commencing the second 12-week treatment phase (cross-over).
| Original language | English |
|---|---|
| Article number | 102870 |
| Number of pages | 1 |
| Journal | Neuroscience Applied |
| Volume | 2 |
| Issue number | Supplement 2 |
| DOIs | |
| Publication status | Published - 2023 |
| Event | Congress of the European-College-of-Neuropsychopharmacology (ECNP) 2023 - Barcelona, Spain Duration: 7 Oct 2023 → 10 Oct 2023 Conference number: 36th https://www.sciencedirect.com/journal/neuroscience-applied/vol/2/suppl/S2 (Published Abstracts) https://www.ecnp.eu/Congress2023/ECNPcongress |